Kurs
+8,25%
Likviditet
152 MDKK
Kalender
| Tid* | ||
| 2025-10-09 | N/A | Årsstämma |
| 2025-09-11 | 08:00 | Bokslutskommuniké 2025 |
| 2025-02-05 | 17:00 | Kvartalsrapport 2025-Q2 |
| 2024-10-11 | - | X-dag ordinarie utdelning CHEMM 4.00 DKK |
| 2024-10-10 | - | Årsstämma |
| 2024-09-11 | - | Bokslutskommuniké 2024 |
| 2024-02-05 | - | Kvartalsrapport 2024-Q2 |
| 2023-10-13 | - | X-dag ordinarie utdelning CHEMM 6.00 DKK |
| 2023-10-12 | - | Årsstämma |
| 2023-09-14 | - | Bokslutskommuniké 2023 |
| 2023-05-09 | - | 15-10 2023-Q3 |
| 2023-02-09 | - | Kvartalsrapport 2023-Q2 |
| 2022-10-14 | - | X-dag ordinarie utdelning CHEMM 0.00 DKK |
| 2022-10-13 | - | Årsstämma |
| 2022-09-15 | - | Bokslutskommuniké 2022 |
| 2022-02-08 | - | Kvartalsrapport 2022-Q2 |
| 2021-10-15 | - | X-dag ordinarie utdelning CHEMM 4.00 DKK |
| 2021-10-14 | - | Årsstämma |
| 2021-09-16 | - | Bokslutskommuniké 2021 |
| 2021-02-05 | - | Kvartalsrapport 2021-Q2 |
| 2020-10-09 | - | X-dag ordinarie utdelning CHEMM 1.50 DKK |
| 2020-10-08 | - | Årsstämma |
| 2020-09-17 | - | Bokslutskommuniké 2020 |
| 2020-02-07 | - | Kvartalsrapport 2020-Q2 |
| 2020-01-14 | - | X-dag bonusutdelning CHEMM 13 |
| 2020-01-13 | - | Extra Bolagsstämma 2020 |
| 2019-10-11 | - | X-dag ordinarie utdelning CHEMM 7.50 DKK |
| 2019-10-10 | - | Årsstämma |
| 2019-09-17 | - | Bokslutskommuniké 2019 |
| 2019-02-08 | - | Kvartalsrapport 2019-Q2 |
| 2018-10-12 | - | X-dag ordinarie utdelning CHEMM 0.00 DKK |
| 2018-10-11 | - | Årsstämma |
| 2018-09-18 | - | Bokslutskommuniké 2018 |
| 2018-02-09 | - | Kvartalsrapport 2018-Q2 |
| 2017-11-15 | - | Årsstämma |
| 2017-10-13 | - | X-dag ordinarie utdelning CHEMM 0.00 DKK |
| 2017-10-12 | - | Årsstämma |
| 2017-09-19 | - | Bokslutskommuniké 2017 |
| 2017-02-10 | - | Kvartalsrapport 2017-Q2 |
| 2016-10-14 | - | X-dag ordinarie utdelning CHEMM 0.00 DKK |
| 2016-10-13 | - | Årsstämma |
| 2016-09-20 | - | Bokslutskommuniké 2016 |
| 2016-02-26 | - | Kvartalsrapport 2016-Q2 |
| 2015-10-09 | - | X-dag ordinarie utdelning CHEMM 0.00 DKK |
| 2015-10-08 | - | Årsstämma |
| 2015-05-15 | - | Kvartalsrapport 2015-Q3 |
| 2014-10-10 | - | X-dag ordinarie utdelning CHEMM 0.00 DKK |
| 2014-10-09 | - | Årsstämma |
| 2014-05-15 | - | Kvartalsrapport 2014-Q3 |
| 2013-11-15 | - | Kvartalsrapport 2014-Q1 |
| 2013-10-11 | - | X-dag ordinarie utdelning CHEMM 0.00 DKK |
| 2013-10-10 | - | Årsstämma |
| 2013-07-25 | - | Extra Bolagsstämma 2013 |
| 2013-05-14 | - | Kvartalsrapport 2013-Q3 |
| 2012-11-14 | - | Kvartalsrapport 2013-Q1 |
| 2012-10-12 | - | X-dag ordinarie utdelning CHEMM 0.00 DKK |
| 2012-10-11 | - | Årsstämma |
| 2012-05-11 | - | Kvartalsrapport 2012-Q3 |
| 2011-11-11 | - | Kvartalsrapport 2012-Q1 |
| 2011-10-14 | - | X-dag ordinarie utdelning CHEMM 0.00 DKK |
| 2011-10-13 | - | Årsstämma |
| 2011-05-13 | - | Kvartalsrapport 2011-Q3 |
| 2010-11-12 | - | Kvartalsrapport 2011-Q1 |
| 2010-10-06 | - | X-dag ordinarie utdelning CHEMM 0.00 DKK |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Large Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
ANNOUNCEMENT NO. 280
16 October 2024
Acquisition of Ovizio Imaging Systems SA
On the basis of the completed due diligence, ChemoMetec today submitted a binding tender offer for the acquisition of 100% of the shares of Belgian company Ovizio Imaging Systems SA (’Ovizio’).
The acquisition price is EUR 2,830,000.
The tender offer has already been accepted by shareholders owning more than two thirds of Ovizio, and ChemoMetec is currently in the process of obtaining acceptance from the remaining shareholders, who are under a legal obligation to accept.
Closing is expected to take place within the coming week and will coincide with the actual acquisition date.
When the acquisition has been completed, ChemoMetec will immediately begin the process of developing Ovizio.
Acquiring Ovizio is not expected to impact ChemoMetec’s most recent guidance.
Additional information
Martin Helbo Behrens, CEO
Tel.: (+45) 48 13 10 20
Kim Nicolajsen, CFO
Tel.: (+45) 48 13 10 20
About Ovizio
Ovizio has developed a cell counter based on holographic microscopy. The instrument is primarily used in bioprocessing and in cell and gene therapy. Ovizio’s product is connected directly to the customers’ bioreactors via a disposable item, which is supplied sterilised and with a high degree of cleanness. With the cell counter, cells can be continuously extracted from the bioreactor for analysis and subsequently returned to the bioreactor. Ovizio has a number of respected customers in the pharmaceutical and biotech industries. In 2023, the company reported revenue of EUR 1.4 million, of which a substantial part was generated through sales of consumables and service contracts.
About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements.
ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.
ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.